Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 347

1.

Abnormal Cardiac Biomarkers in Patients with Systemic Lupus Erythematosus and No Prior Heart Disease: A Consequence of Antimalarials?

Tselios K, Gladman DD, Harvey P, Akhtari S, Su J, Urowitz MB.

J Rheumatol. 2018 Aug 1. pii: jrheum.171436. doi: 10.3899/jrheum.171436. [Epub ahead of print]

PMID:
30068764
2.

Practice Variations in the Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus in Canada.

Keeling SO, Bissonauth A, Bernatsky S, Vandermeer B, Fortin PR, Gladman DD, Peschken C, Urowitz MB.

J Rheumatol. 2018 Aug 1. pii: jrheum.171307. doi: 10.3899/jrheum.171307. [Epub ahead of print]

3.

Clinical remission and low disease activity have comparable outcomes over 10 years in systemic lupus erythematosus.

Tselios K, Gladman DD, Touma Z, Su J, Anderson N, Urowitz MB.

Arthritis Care Res (Hoboken). 2018 Jul 28. doi: 10.1002/acr.23720. [Epub ahead of print]

PMID:
30055090
4.

Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort.

Choi MY, Clarke AE, St Pierre Y, Hanly JG, Urowitz MB, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Petri M, Bruce IN, Dooley MA, Fortin PR, Gladman DD, Sanchez-Guerrero J, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Alarcón GS, Manzi S, Nived O, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Stoll T, Buyon J, Mahler M, Fritzler MJ.

Arthritis Care Res (Hoboken). 2018 Jul 25. doi: 10.1002/acr.23712. [Epub ahead of print]

PMID:
30044551
5.

Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines.

Jorge AM, Melles RB, Zhang Y, Lu N, Rai SK, Young LH, Costenbader KH, Ramsey-Goldman R, Lim SS, Esdaile JM, Clarke AE, Urowitz MB, Askanase A, Aranow C, Petri M, Choi H.

Arthritis Res Ther. 2018 Jul 5;20(1):133. doi: 10.1186/s13075-018-1634-8.

6.

Monophasic Disease Course in Systemic Lupus Erythematosus.

Tselios K, Gladman DD, Touma Z, Su J, Anderson N, Urowitz MB.

J Rheumatol. 2018 Aug;45(8):1131-1135. doi: 10.3899/jrheum.171319. Epub 2018 Jun 1.

PMID:
29858240
7.

A novel lupus activity index accounting for glucocorticoids: SLEDAI-2K glucocorticoid index.

Touma Z, Gladman DD, Su J, Anderson N, Urowitz MB.

Rheumatology (Oxford). 2018 Aug 1;57(8):1370-1376. doi: 10.1093/rheumatology/key103.

PMID:
29688532
8.

Severe brady-arrhythmias in systemic lupus erythematosus: prevalence, etiology and associated factors.

Tselios K, Gladman DD, Harvey P, Su J, Urowitz MB.

Lupus. 2018 Aug;27(9):1415-1423. doi: 10.1177/0961203318770526. Epub 2018 Apr 17.

PMID:
29665757
9.

Lupus myocarditis: a single center experience and a comparative analysis of observational cohort studies.

Tanwani J, Tselios K, Gladman DD, Su J, Urowitz MB.

Lupus. 2018 Jul;27(8):1296-1302. doi: 10.1177/0961203318770018. Epub 2018 Apr 11.

PMID:
29642752
10.

Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort.

Little J, Parker B, Lunt M, Hanly JG, Urowitz MB, Clarke AE, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Wallace DJ, Merrill JT, Buyon J, Isenberg DA, Rahman A, Ginzler EM, Petri M, Dooley MA, Fortin P, Gladman DD, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Mackay M, Alarcón GS, Manzi S, Nived O, Jönsen A, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Sam Lim S, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Sanchez-Guerrero J, Bruce IN.

Rheumatology (Oxford). 2018 Apr 1;57(4):677-687. doi: 10.1093/rheumatology/kex444.

PMID:
29361147
11.

Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus.

Bernatsky S, Ramsey-Goldman R, Petri M, Urowitz MB, Gladman DD, Fortin PR, Yelin EH, Ginzler E, Hanly JG, Peschken C, Gordon C, Nived O, Aranow C, Bae SC, Isenberg D, Rahman A, Hansen JE, Pierre YS, Clarke AE.

J Rheumatol. 2018 Mar;45(3):393-396. doi: 10.3899/jrheum.170652. Epub 2018 Jan 15.

PMID:
29335347
12.

Cerebrovascular Events in Systemic Lupus Erythematosus.

Hanly JG, Li Q, Su L, Urowitz MB, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Clarke AE, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Fortin P, Gladman DD, Bruce IN, Petri M, Ginzler EM, Dooley MA, Steinsson K, Ramsey-Goldman R, Zoma AA, Manzi S, Nived O, Jonsen A, Khamashta MA, Alarcón GS, Chatham W, van Vollenhoven RF, Aranow C, Mackay M, Ruiz-Irastorza G, Ramos-Casals M, Lim SS, Inanc M, Kalunian KC, Jacobsen S, Peschken CA, Kamen DL, Askanase A, Theriault C, Farewell V.

Arthritis Care Res (Hoboken). 2018 Jan 5. doi: 10.1002/acr.23509. [Epub ahead of print]

PMID:
29316357
13.

Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study.

Ferreira I, Croca S, Raimondo MG, Matharu M, Miller S, Giles I, Isenberg D, Ioannou Y, Hanly JG, Urowitz MB, Anderson N, Aranow C, Askanase A, Bae SC, Bernatsky S, Bruce IN, Buyon J, Clarke AE, Dooley MA, Fortin P, Ginzler E, Gladman D, Gordon C, Inanc M, Jacobsen S, Kalunian K, Kamen D, Khamashta M, Lim S, Manzi S, Merrill J, Nived O, Peschken C, Petri M, Ramsey-Goldman R, Ruiz-Irastorza G, Sanchez-Guerrero J, Steinson K, Sturfelt GK, van Vollenhoven R, Wallace DJ, Zoma A, Rahman A.

Arthritis Res Ther. 2017 Dec 22;19(1):287. doi: 10.1186/s13075-017-1495-6.

14.

Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach.

Barber MRW, Hanly JG, Su L, Urowitz MB, St Pierre Y, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Wallace DJ, Isenberg DA, Rahman A, Ginzler EM, Petri M, Bruce IN, Fortin PR, Gladman DD, Sanchez-Guerrero J, Ramsey-Goldman R, Khamashta MA, Aranow C, Mackay M, Alarcón GS, Manzi S, Nived O, Jönsen A, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Theriault C, Farewell V, Clarke AE.

Arthritis Care Res (Hoboken). 2017 Nov 28. doi: 10.1002/acr.23480. [Epub ahead of print]

PMID:
29193883
15.

More Consistent Antimalarial Intake in First 5 Years of Disease Is Associated with Better Prognosis in Patients with Systemic Lupus Erythematosus.

Pakchotanon R, Gladman DD, Su J, Urowitz MB.

J Rheumatol. 2018 Jan;45(1):90-94. doi: 10.3899/jrheum.170645. Epub 2017 Nov 15.

PMID:
29142038
16.

Evolution of Risk Factors for Atherosclerotic Cardiovascular Events in Systemic Lupus Erythematosus: A Longterm Prospective Study.

Tselios K, Gladman DD, Su J, Ace O, Urowitz MB.

J Rheumatol. 2017 Dec;44(12):1841-1849. doi: 10.3899/jrheum.161121. Epub 2017 Nov 1.

PMID:
29093154
17.

Rituximab for Sight-Threatening Lupus-Related Retinal Vasculitis.

Tselios K, Lam WC, Urowitz MB, Gladman DD.

J Clin Rheumatol. 2018 Mar;24(2):93-94. doi: 10.1097/RHU.0000000000000600. No abstract available.

PMID:
29059086
18.

Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index.

Kalunian KC, Urowitz MB, Isenberg D, Merrill JT, Petri M, Furie RA, Morgan-Cox MA, Taha R, Watts S, Silk M, Linnik MD.

Rheumatology (Oxford). 2018 Jan 1;57(1):125-133. doi: 10.1093/rheumatology/kex368.

PMID:
29045736
19.

Antimalarial-induced cardiomyopathy: a systematic review of the literature.

Tselios K, Deeb M, Gladman DD, Harvey P, Urowitz MB.

Lupus. 2018 Apr;27(4):591-599. doi: 10.1177/0961203317734922. Epub 2017 Oct 9.

PMID:
28992800
20.

Sustained complete renal remission is a predictor of reduced mortality, chronic kidney disease and end-stage renal disease in lupus nephritis.

Pakchotanon R, Gladman DD, Su J, Urowitz MB.

Lupus. 2018 Mar;27(3):468-474. doi: 10.1177/0961203317726376. Epub 2017 Aug 31.

PMID:
28857717
21.

Shrinking lung syndrome in systemic lupus erythematosus: a single-centre experience.

Deeb M, Tselios K, Gladman DD, Su J, Urowitz MB.

Lupus. 2018 Mar;27(3):365-371. doi: 10.1177/0961203317722411. Epub 2017 Jul 31.

PMID:
28758573
22.

Reply.

Urowitz MB, Gladman DD.

Arthritis Care Res (Hoboken). 2017 Dec;69(12):1934. doi: 10.1002/acr.23309. No abstract available.

PMID:
28686813
23.

Cardiovascular and Pulmonary Manifestations of Systemic Lupus Erythematosus.

Tselios K, Urowitz MB.

Curr Rheumatol Rev. 2017;13(3):206-218. doi: 10.2174/1573397113666170704102444. Review.

PMID:
28675998
24.

Hospitalizations in Patients with Systemic Lupus Erythematosus in an Academic Health Science Center.

Gu K, Gladman DD, Su J, Urowitz MB.

J Rheumatol. 2017 Aug;44(8):1173-1178. doi: 10.3899/jrheum.170072. Epub 2017 Jun 15.

PMID:
28620060
25.

Breast cancer in systemic lupus erythematosus (SLE): receptor status and treatment.

Chan K, Clarke AE, Ramsey-Goldman R, Foulkes W, Tessier Cloutier B, Urowitz MB, Gladman D, Nived O, Romero-Diaz J, Petri M, Ginzler E, Fortin PR, Bae SC, Wallace DJ, Yelin EH, Bernatsky S.

Lupus. 2018 Jan;27(1):120-123. doi: 10.1177/0961203317713146. Epub 2017 Jun 8.

PMID:
28595511
26.

Comparison of systemic lupus erythematosus (SLE) patients managed early after diagnosis in specialty versus community care clinics.

Aljohani R, Gladman DD, Su J, Urowitz MB.

Clin Rheumatol. 2017 Aug;36(8):1773-1778. doi: 10.1007/s10067-017-3713-7. Epub 2017 Jun 6.

PMID:
28589322
27.

Osteonecrosis in SLE: prevalence, patterns, outcomes and predictors.

Gladman DD, Dhillon N, Su J, Urowitz MB.

Lupus. 2018 Jan;27(1):76-81. doi: 10.1177/0961203317711012. Epub 2017 May 22.

PMID:
28530464
28.

Disease evolution in late-onset and early-onset systemic lupus erythematosus.

Aljohani R, Gladman DD, Su J, Urowitz MB.

Lupus. 2017 Oct;26(11):1190-1196. doi: 10.1177/0961203317696593. Epub 2017 Mar 12.

PMID:
28420066
29.

The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients.

Choi MY, Clarke AE, St Pierre Y, Hanly JG, Urowitz MB, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Petri M, Bruce IN, Dooley MA, Fortin P, Gladman DD, Sanchez-Guerrero J, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Alarcón GS, Manzi S, Nived O, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Buyon J, Mahler M, Fritzler MJ.

Lupus. 2017 Sep;26(10):1051-1059. doi: 10.1177/0961203317692437. Epub 2017 Feb 23.

PMID:
28420054
30.

Prevalence and associated factors of resting electrocardiogram abnormalities among systemic lupus erythematosus patients without cardiovascular disease.

Al Rayes H, Harvey PJ, Gladman DD, Su J, Sabapathy A, Urowitz MB, Touma Z.

Arthritis Res Ther. 2017 Feb 10;19(1):31. doi: 10.1186/s13075-017-1240-1.

31.

Psoriasis in systemic lupus erythematosus: a single-center experience.

Tselios K, Yap KS, Pakchotanon R, Polachek A, Su J, Urowitz MB, Gladman DD.

Clin Rheumatol. 2017 Apr;36(4):879-884. doi: 10.1007/s10067-017-3566-0. Epub 2017 Feb 6.

PMID:
28168661
32.

Systemic lupus erythematosus and pulmonary arterial hypertension: links, risks, and management strategies.

Tselios K, Gladman DD, Urowitz MB.

Open Access Rheumatol. 2016 Dec 20;9:1-9. doi: 10.2147/OARRR.S123549. eCollection 2017. Review.

33.

The utility of lupus serology in predicting outcomes of renal transplantation in lupus patients: Systematic literature review and analysis of the Toronto lupus cohort.

Yap KS, Urowitz MB, Mahood Q, Medina-Rosas J, Sabapathy A, Lawson D, Su J, Gladman DD, Touma Z.

Semin Arthritis Rheum. 2017 Jun;46(6):791-797. doi: 10.1016/j.semarthrit.2016.09.008. Epub 2016 Sep 21.

PMID:
27769590
34.

Defining Low Disease Activity in Systemic Lupus Erythematosus.

Polachek A, Gladman DD, Su J, Urowitz MB.

Arthritis Care Res (Hoboken). 2017 Jul;69(7):997-1003. doi: 10.1002/acr.23109.

35.

Breast cancer in systemic lupus.

Bernatsky S, Ramsey-Goldman R, Petri M, Urowitz MB, Gladman DD, Fortin PF, Ginzler E, Romero-Diaz J, Peschken C, Jacobsen S, Hanly JG, Gordon C, Nived O, Yelin EH, Isenberg D, Rahman A, Bae SC, Joseph L, Witte T, Ruiz-Irastorza G, Aranow C, Kamen D, Sturfeldt G, Foulkes WD, Hansen JE, St Pierre Y, Raymer PC, Tessier-Cloutier B, Clarke AE.

Lupus. 2017 Mar;26(3):311-315. doi: 10.1177/0961203316664595. Epub 2016 Sep 30.

36.

Dr. Tselios, et al reply.

Tselios K, Gladman DD, Su J, Urowitz MB.

J Rheumatol. 2016 Sep;43(9):1767. doi: 10.3899/jrheum.160749. No abstract available.

PMID:
27587017
37.

Prevalence and associated factors of low bone mass in adults with systemic lupus erythematosus.

Cramarossa G, Urowitz MB, Su J, Gladman D, Touma Z.

Lupus. 2017 Apr;26(4):365-372. doi: 10.1177/0961203316664597. Epub 2016 Aug 20.

PMID:
27522094
38.

Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis.

Miloslavsky EM, Naden RP, Bijlsma JW, Brogan PA, Brown ES, Brunetta P, Buttgereit F, Choi HK, DiCaire JF, Gelfand JM, Heaney LG, Lightstone L, Lu N, Murrell DF, Petri M, Rosenbaum JT, Saag KS, Urowitz MB, Winthrop KL, Stone JH.

Ann Rheum Dis. 2017 Mar;76(3):543-546. doi: 10.1136/annrheumdis-2016-210002. Epub 2016 Jul 29.

39.

Hydroxychloroquine-Induced Cardiomyopathy in Systemic Lupus Erythematosus.

Tselios K, Gladman DD, Harvey P, Mak S, Chantal M, Butany J, Urowitz MB.

J Clin Rheumatol. 2016 Aug;22(5):287-8. doi: 10.1097/RHU.0000000000000400. No abstract available.

PMID:
27464781
40.

Systemic lupus erythematosus.

Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, Ruiz-Irastorza G, Hughes G.

Nat Rev Dis Primers. 2016 Jun 16;2:16039. doi: 10.1038/nrdp.2016.39. Review.

PMID:
27306639
41.

Disease Outcomes in Glucocorticosteroid-Naive Patients With Systemic Lupus Erythematosus.

Sheane BJ, Gladman DD, Su J, Urowitz MB.

Arthritis Care Res (Hoboken). 2017 Feb;69(2):252-256. doi: 10.1002/acr.22938.

42.

Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort.

Urowitz MB, Gladman DD, Anderson NM, Su J, Romero-Diaz J, Bae SC, Fortin PR, Sanchez-Guerrero J, Clarke A, Bernatsky S, Gordon C, Hanly JG, Wallace DJ, Isenberg D, Rahman A, Merrill J, Ginzler E, Alarcón GS, Fessler BF, Petri M, Bruce IN, Khamashta M, Aranow C, Dooley M, Manzi S, Ramsey-Goldman R, Sturfelt G, Nived O, Steinsson K, Zoma A, Ruiz-Irastorza G, Lim S, Kalunian KC, Ỉnanç M, van Vollenhoven R, Ramos-Casals M, Kamen DL, Jacobsen S, Peschken C, Askanase A, Stoll T.

Lupus Sci Med. 2016 Apr 12;3(1):e000143. doi: 10.1136/lupus-2015-000143. eCollection 2016. Erratum in: Lupus Sci Med. 2016;3(1):e000143corr1.

43.

A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach.

Hanly JG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Clarke AE, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Petri M, Bruce IN, Dooley MA, Fortin P, Gladman DD, Sanchez-Guerrero J, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Alarcón GS, Fessler BJ, Manzi S, Nived O, Sturfelt GK, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Theriault C, Farewell V.

Arthritis Rheumatol. 2016 Aug;68(8):1932-44. doi: 10.1002/art.39674.

44.

Modified Framingham Risk Factor Score for Systemic Lupus Erythematosus.

Urowitz MB, Ibañez D, Su J, Gladman DD.

J Rheumatol. 2016 May;43(5):875-9. doi: 10.3899/jrheum.150983. Epub 2016 Feb 15.

PMID:
26879352
45.

Does Renin-Angiotensin System Blockade Protect Lupus Nephritis Patients From Atherosclerotic Cardiovascular Events? A Case-Control Study.

Tselios K, Gladman DD, Su J, Urowitz MB.

Arthritis Care Res (Hoboken). 2016 Oct;68(10):1497-504. doi: 10.1002/acr.22857. Epub 2016 Aug 19.

46.

Mycophenolate Mofetil in Nonrenal Manifestations of Systemic Lupus Erythematosus: An Observational Cohort Study.

Tselios K, Gladman DD, Su J, Urowitz MB.

J Rheumatol. 2016 Mar;43(3):552-8. doi: 10.3899/jrheum.150779. Epub 2016 Jan 15.

PMID:
26773121
47.

Dyslipidemia in systemic lupus erythematosus: just another comorbidity?

Tselios K, Koumaras C, Gladman DD, Urowitz MB.

Semin Arthritis Rheum. 2016 Apr;45(5):604-10. doi: 10.1016/j.semarthrit.2015.10.010. Epub 2015 Oct 29. Review.

PMID:
26711309
48.

Antimalarials as a risk factor for elevated muscle enzymes in systemic lupus erythematosus.

Tselios K, Gladman DD, Su J, Urowitz MB.

Lupus. 2016 Apr;25(5):532-5. doi: 10.1177/0961203315617845. Epub 2015 Nov 18.

PMID:
26585070
49.

Optimal Monitoring For Coronary Heart Disease Risk in Patients with Systemic Lupus Erythematosus: A Systematic Review.

Tselios K, Sheane BJ, Gladman DD, Urowitz MB.

J Rheumatol. 2016 Jan;43(1):54-65. doi: 10.3899/jrheum.150460. Epub 2015 Nov 15. Review.

PMID:
26568591
50.

Lack of Interferon and Proinflammatory Cyto/chemokines in Serologically Active Clinically Quiescent Systemic Lupus Erythematosus.

Steiman AJ, Gladman DD, Ibañez D, Noamani B, Landolt-Marticorena C, Urowitz MB, Wither JE.

J Rheumatol. 2015 Dec;42(12):2318-26. doi: 10.3899/jrheum.150040. Epub 2015 Nov 15.

PMID:
26568589

Supplemental Content

Loading ...
Support Center